{"id":1009048,"date":"2026-10-09T18:20:04","date_gmt":"2026-10-09T22:20:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/"},"modified":"2026-10-09T18:20:04","modified_gmt":"2026-10-09T22:20:04","slug":"aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/","title":{"rendered":"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN FRANCISCO, Oct.  09, 2026  (GLOBE NEWSWIRE) &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (<strong>NASDAQ: $AARD<\/strong>) of a pending securities class action lawsuit.<\/p>\n<p>Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company\u2019s initial public offering (<strong>IPO<\/strong>) on or about <strong>February 13, 2025<\/strong>, and\/or purchased or acquired Aardvark securities between <strong>February 13, 2025 and May 14, 2026<\/strong> (the <strong>Class Period<\/strong>), are encouraged to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7xErNaknU5124FQ5qZb_kKNzVOd4Q_H8NpZdroEbfzGhFAoUORMcZ1BsF_lO3jiZ_frXaeq6kJZvhrlvxpJL0elsVz-EtX4pgsiXAyxVG__hh8ZKfKVxxVcs_-1hkvwU5KjBPrc-3cwP3z_rsi4zw8rc11nBx2mjuHynAcpW3Vl6e8NrU_LFpUrW2ND46iIl\" rel=\"nofollow\" target=\"_blank\">contact our firm now<\/a>.<\/p>\n<p>\n        <strong>Key Case Details &amp; Important Deadlines<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt\">\n          <strong>Lead Plaintiff Motion Deadline:<\/strong><br \/>\n          <strong>October 13, 2026<\/strong>\n        <\/li>\n<li style=\"margin-top:5pt\">\n          <strong>Visit:<\/strong><br \/>\n          <a href=\"https:\/\/www.hbsslaw.com\/cases\/aardvark-therapeutics-inc-aard-securities-class-action\" rel=\"nofollow\" target=\"_blank\">www.hbsslaw.com\/aard<\/a>\n        <\/li>\n<li style=\"margin-top:5pt\">\n          <strong>Contact the Firm Now: <\/strong><br \/>\n          <a href=\"mailto:AARD@hbsslaw.com\" rel=\"nofollow\" target=\"_blank\">AARD@hbsslaw.com<\/a><br \/>\n          <br \/>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0844-916-0895<\/li>\n<\/ul>\n<p>\n        <strong>Watch our video on the Aardvark investigation: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dXQqia8cTHihZJr97A3Pz2VZ4AtUk9-FIsaeB_K6Ay8P7BMqaDxViga8rDeHRXDlIJghUFfEDf_dQ7DOTRc9VxOjFtIwpGxUKqThsSrjpds=\" rel=\"nofollow\" target=\"_blank\">youtu.be\/pY5E36QoCqo<\/a>\n      <\/p>\n<p>\n        <strong>What is the Lawsuit About?<\/strong>\n      <\/p>\n<p>The complaint alleges that Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting bitter taste receptors (TAS2Rs) such as ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS), made materially false and misleading statements and\/or failed to disclose critical information.<\/p>\n<p>Specifically, the action points out that the offering documents and defendants failed to disclose:<\/p>\n<ol style=\"list-style-type:decimal\">\n<li style=\"margin-top:5pt\">That <strong>ARD-101<\/strong> was significantly less safe than defendants had led investors to believe;<\/li>\n<li style=\"margin-top:5pt\">That unexpected, reversible cardiac observations (such as QRS prolongation) occurred during trials at above-target doses; and<\/li>\n<li style=\"margin-top:5pt\">Consequently, Aardvark\u2019s clinical, regulatory, and commercial prospects\u2014including the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE)\u2014were materially overstated.\n<\/li>\n<\/ol>\n<p>\n        <strong>The Truth Emerges: Voluntarily Pause and FDA Clinical Hold<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>February 27, 2026<\/strong>: Aardvark announced it was voluntarily pausing its Phase 3 HERO trial due to &#8220;reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study.&#8221; Following this news, Aardvark&#8217;s stock price plummeted over <strong>56%<\/strong>.<\/li>\n<li>\n          <strong>May 14, 2026<\/strong>: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and OLE trial. Aardvark\u2019s stock price fell another <strong>32.1%<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>Hagens Berman\u2019s Investigation<\/strong>\n      <\/p>\n<p>\u201cWe\u2019re investigating the suit\u2019s allegations, including that Aardvark allegedly misled investors about ARD-101\u2019s development, its safety and efficacy,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QincaBJ7Lc5YkS5RlPao_Z_sl3xOyyuU_IZ5s1cQvt7Q9nerKRfxQBZwQOhTc4k2qm42hgNeCnhoFT8bVECrLAyKf-vw8e-Thg1X9oo5jX9JA7tq5mHS1T1WkO1CBVi0\" rel=\"nofollow\" target=\"_blank\"><strong>Reed Kathrein<\/strong><\/a>, the Hagens Berman partner leading the firm\u2019s investigation of the claims in the pending suit.<\/p>\n<p>\n        <strong>What Can Aardvark Investors Do?<\/strong>\n      <\/p>\n<p>If you are a class member who suffered losses on Aardvark securities, you have until <strong>October 13, 2026<\/strong>, to ask the Court to appoint you as Lead Plaintiff for the class. The firm welcomes AARD investors to contact the firm to discuss their legal rights and potential recovery options.<\/p>\n<ul type=\"disc\">\n<li>\n          <a href=\"https:\/\/www.hbsslaw.com\/cases\/aardvark-therapeutics-inc-aard-securities-class-action\" rel=\"nofollow\" target=\"_blank\">Submit Your Information to Hagens Berman<\/a>\n        <\/li>\n<li style=\"margin-top:5pt\">\n          <strong>Contact an Attorney: <\/strong><br \/>\n          <a href=\"mailto:AARD@hbsslaw.com\" rel=\"nofollow\" target=\"_blank\">AARD@hbsslaw.com<\/a><br \/>\n          <br \/>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 844-916-0895<\/li>\n<\/ul>\n<p>If you\u2019d like more information and answers to frequently asked questions about the firm\u2019s Aardvark investigation, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dp0kwPJw66Xehk5OItpb5kEN_v-sqxkAWEwIAfCzS5hJykyEXP7qkDYywJS5YtUNIqCsMOJYx7jGM-8Wj5MihwZ9NThFCgv02EkVd2OvNl8vEHopzObcj6GipIMn5UQ0q4yxfF00KXE2Qu080MTRvXUvHatgpyBEDOaPpvkMSbo=\" rel=\"nofollow\" target=\"_blank\">read more<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FVjIuOU3gszrdryO2RoUQF3uyFctxjBD35YNQj0duU5ED0SVQOgEvKQufaluK5jTnIlp9Cc_p0bsqR4_m3WgEuGGbl0MsaawgPNLSKX3g23lhvZlfsxWVa7MkhXrRKLN-XZNpQJhFu7guHglimfYLuNPts-cV59lthu4r1f3rlg=\" rel=\"nofollow\" target=\"_blank\"> \u00bb<\/a><\/p>\n<p>\n        <strong>Whistleblowers: <\/strong>Persons with non-public information regarding Aardvark Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <strong>844-916-0895<\/strong> or email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jprcr8mWjYF6UDbrWHu2tG6FHRuNpdD0fIgSrfK-fOndsUTPKNkNbFE1SjJl5Riw-oZa29UBHefZz46fm7Vd4UM6Iz0_Ivj_AVcthw4--v8=\" rel=\"nofollow\" target=\"_blank\">AARD@hbsslaw.com<\/a><\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nSOaic6UhEbXpUdQVhqj1Nfc1hO_U_uHt9SQAallotJlkUIvf9STtTRpHbaTWslIt2yK9aVSJ3SjIRuwWkE46E7mg2fYVShaIuem4xqCrrY=\" rel=\"nofollow\" target=\"_blank\">About Hagens Berman<\/a><br \/>\n        <br \/>Hagens Berman is a global plaintiffs\u2019 rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman\u2019s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UjE4__34ZUadvcGKw0IGCPR8glh7-DnclyX153u9KU9nZBaZ7pyL5d_bEABqiOCDLgTvkgAnC048zYakihJbMg==\" rel=\"nofollow\" target=\"_blank\">hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cweY7h0qCRZk8NpsAywhYAXwSApXEiX2Li13aaRyRgAkCVGZz_RImlNnJjuT4S68-6GS79c1lRqODu031ZO0rW6t-KeJPIbegsxGvKSc3cnTaPOuz1EbZMw5_zNZ5voT\" rel=\"nofollow\" target=\"_blank\">@ClassActionLaw<\/a>.\u00a0<\/p>\n<p>Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.<\/p>\n<p>Contact:\u00a0Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, <strong>844-916-0895, <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jprcr8mWjYF6UDbrWHu2tFPB9m5sUCXsk1ctTT9zDdpgWFVgeedk_abCAvaKgAIxqySMjzrKXcJ37UKBY5BKcQcple48S-EVwDgRmHAGYww=\" rel=\"nofollow\" target=\"_blank\">AARD@hbsslaw.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTMzM2ZjZjgtYmI1YS00MDY4LWFlMTYtZGYzZDZjODE0NjRiLTEwMzAxMDUtMjAyNi0xMC0wOS1lbg==\/tiny\/Hagens-Berman-Sobol-Shapiro-LL.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: $AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company\u2019s initial public offering (IPO) on or about February 13, 2025, and\/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now. Key Case Details &amp; Important Deadlines Lead Plaintiff Motion Deadline: October 13, 2026 Visit: www.hbsslaw.com\/aard Contact the Firm Now: AARD@hbsslaw.com \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009048","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: $AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company\u2019s initial public offering (IPO) on or about February 13, 2025, and\/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now. Key Case Details &amp; Important Deadlines Lead Plaintiff Motion Deadline: October 13, 2026 Visit: www.hbsslaw.com\/aard Contact the Firm Now: AARD@hbsslaw.com \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; Continue reading &quot;AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-09T22:20:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS\",\"datePublished\":\"2026-10-09T22:20:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/\"},\"wordCount\":668,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/\",\"name\":\"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=\",\"datePublished\":\"2026-10-09T22:20:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/","og_locale":"en_US","og_type":"article","og_title":"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS - Market Newsdesk","og_description":"SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: $AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and\/or traceable to the offering documents issued in connection with the Company\u2019s initial public offering (IPO) on or about February 13, 2025, and\/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now. Key Case Details &amp; Important Deadlines Lead Plaintiff Motion Deadline: October 13, 2026 Visit: www.hbsslaw.com\/aard Contact the Firm Now: AARD@hbsslaw.com \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; Continue reading \"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-09T22:20:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS","datePublished":"2026-10-09T22:20:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/"},"wordCount":668,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/","name":"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=","datePublished":"2026-10-09T22:20:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzMwNSM3ODg4MjkzIzIwMTg1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aard-4-day-deadline-alert-aardvark-therapeutics-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-before-october-13-2026-lead-plaintiff-deadline-hbss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline &#8211; HBSS"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009048"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009048\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}